Glatiramer acetate (GA) is an immunomodulator approved for therapy of relapsing-remitting multiple sclerosis (RRMS), but recent findings indicate that it may also have additional, neurotrophic effects. Here, we found that supernatants from human GA-reactive T lymphocytes potentiated oligodendrocyte numbers in rodent and human oligodendrocyte progenitor (OPC) cultures. Effects of Th2-polarized lines were stronger than Th1-polarized cells. Microarray and ELISA analyses revealed that neurotrophic factors induced in Th2-and Th1-polarized GA-reactive lines included IGF-2 and BMP-7 respectively, and functional studies confirmed IGF-2 as trophic for OPCs. Our results support the concept that GA therapy may result in supportive effects on oligodendrocytes in RRMS patients.
Introduction
Glatiramer acetate (GA) is a synthetic copolymer approved for therapy of the relapsing-remitting form of multiple sclerosis (RRMS), an autoimmune demyelinating disease of the CNS that is the most common nontraumatic cause of paralysis in young adults (Blanchette and Neuhaus, 2008; Wolinsky, 2006) . Until recently, work on the mechanism of action of GA has focused primarily on its immunomodulatory effects on T lymphocytes and antigen presenting cells (APCs). GA has been shown to bind to major histocompatibility complex (MHC) molecules on the surface of APCs and prevent binding of myelin basic protein (MBP) and subsequent activation of T helper 1 (Th1) or Th17 encephalitogenic lymphocytes (Fridkis-Hareli et al., 1999; Fridkis-Hareli and Strominger, 1998; Gran et al., 2000) . Interestingly, GA-reactive T cells are also known to be present in the circulation of most individuals, and are predominantly of a Th2 phenotype (Aharoni et al., 1997; Chen et al., 2002; Dhib-Jalbut et al., 2003; Neuhaus et al., 2000) . Activation of these cells in the CNS leads to suppression of autoaggressive myelin-specific Th1 lymphocytes (Aharoni et al., 1998) . GA-reactive Th2 lymphocytes are believed to act as key mediators of the beneficial effects of the drug in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, and have been shown to transfer protection to untreated animals (Arnon and Aharoni, 2004). GA treatment in vivo has also been shown to induce type-2 ('anti-inflammatory') myeloid cell differentiation (with consequent Th2 T cell differentiation) in both MS patients (Kim et al., 2004b) and in the context of EAE (Weber et al., 2007 (Weber et al., , 2004 . The ability to induce CD4 + CD25 + regulatory T cells (Tregs) is also considered as one of the immune mediated therapeutic mechanisms of GA in EAE (Jee et al., 2007) as well as in a model of type 1 diabetes (Cui et al., 2009 ). Recent findings have implied an additional, neurotrophic mechanism of action of GA in MS, suggesting an additional role for GA therapy beyond immunoregulation. In demyelinating models, GA treatment has been shown to result in elevated CNS levels of neurotrophic factors including brain derived neurotrophic factor (BDNF), neurotrophins-3 and -4 (NT3, NT4), and insulin-like growth factor-1 (IGF-1) (Aharoni et al., 2005; Skihar et al., 2009) . Strikingly, human GA-reactive T lymphocytes have also been shown to express both BDNF and IGF-1 (Chen et al., 2003; Skihar et al., 2009; Ziemssen et al., 2002) . While these factors have important effects on neurons, they are also significant regulators of oligodendrocyte lineage cells, which are the myelin-forming cells in the CNS and the target of immune attack in MS (Raine et al., 1997) . Oligodendrocyte progenitor cells (OPCs) are the main source of new myelin in repairing lesions in
